Beta-Blockers vs ACE Inhibitors vs ARBs: Heart Failure Pharmacology
Three drug classes form the backbone of guideline-directed heart failure therapy. Here is exactly how beta-blockers, ACE inhibitors, and ARBs differ in mechanism, nursing monitoring, and NCLEX-priority assessments.
Learning Objectives
- Distinguish beta-blockers, ACE inhibitors, and ARBs by mechanism and indication.
- Identify the key labs and vital signs to monitor with each class.
- Recognize ACE-inhibitor cough vs angioedema and the conversion to ARB therapy.
1. Direct Answer: Three Mechanisms, One Goal
Heart failure with reduced ejection fraction (HFrEF) is treated with GUIDELINE-DIRECTED MEDICAL THERAPY (GDMT) — beta-blockers, ACE inhibitors or ARBs, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — all of which improve survival. BETA-BLOCKERS (carvedilol, metoprolol succinate, bisoprolol) block beta-1 cardiac receptors to slow heart rate, reduce contractility, lower myocardial oxygen demand, and over months reverse pathologic remodeling. ACE INHIBITORS (lisinopril, enalapril, captopril) block conversion of angiotensin I to II, dropping vasoconstriction, aldosterone, and afterload while also raising bradykinin (which causes the classic dry cough). ARBs (losartan, valsartan, candesartan) block angiotensin II at the AT1 receptor — the same downstream effects without bradykinin elevation, so no cough. NCLEX priorities differ for each: beta-blockers focus on heart rate and BP at administration; ACE inhibitors and ARBs focus on K+, creatinine, and angioedema.
Key Points
- •Beta-blockers: block beta-1, reduce HR/contractility, reverse remodeling.
- •ACE inhibitors: block A-I → A-II, reduce afterload + aldosterone; cause cough.
- •ARBs: block angiotensin II receptor; same effect without cough.
2. Beta-Blockers: Nursing Considerations
ONLY THREE BETA-BLOCKERS are guideline-recommended for HFrEF (carvedilol and metoprolol succinate also carry an FDA heart failure indication): carvedilol (alpha-1 and non-selective beta), metoprolol SUCCINATE (extended-release, beta-1 selective), and bisoprolol (beta-1 selective). Metoprolol TARTRATE (immediate-release) is NOT a HF agent — students confuse the two routinely. Initiate at LOW dose and titrate slowly over weeks; rapid initiation in decompensated HF can worsen failure. HOLD parameters: SBP < 90 or HR < 50, or new symptoms of decompensation. Side effects: bradycardia, hypotension, fatigue, depression, masked hypoglycemia (in diabetes — patients may not feel the tachycardia warning), bronchospasm with non-selective agents in asthma. Patient teaching: never stop abruptly (rebound tachycardia, MI risk), monitor pulse at home, get up slowly from sitting.
Key Points
- •Only carvedilol, metoprolol SUCCINATE, and bisoprolol are HF beta-blockers.
- •Hold for HR < 50 or SBP < 90 unless ordered otherwise.
- •Never stop abruptly — taper over 1-2 weeks.
3. ACE Inhibitors: Nursing Considerations
First-line for HFrEF unless contraindicated. Watch FIRST-DOSE HYPOTENSION — monitor BP closely after the first dose, especially in volume-depleted patients or those on diuretics. MONITOR LABS: serum potassium (ACE inhibitors raise K+ by decreasing aldosterone), serum creatinine (a rise of up to about 30% as efferent arteriole vasoconstriction is removed is generally acceptable), BUN. CONTRAINDICATIONS: pregnancy (teratogenic, BLACK BOX), bilateral renal artery stenosis (precipitous renal failure), history of angioedema. SIDE EFFECTS: dry persistent cough (common, from bradykinin), hyperkalemia, hypotension, acute kidney injury, ANGIOEDEMA (swelling of lips, tongue, throat — emergency, discontinue immediately and never re-challenge). Patient teaching: monitor for cough/swelling, avoid potassium supplements and salt substitutes (which contain KCl), report symptoms of dehydration.
Key Points
- •First-dose hypotension — monitor BP closely after the first dose.
- •Watch K+, creatinine; a rise up to about 30% is often acceptable.
- •Angioedema is emergent — never re-challenge with another ACE inhibitor.
4. ARBs: When ACE Doesn't Work
ARBs are second-line for patients who cannot tolerate ACE inhibitors due to COUGH (the most common reason for switching) or angioedema (still a risk on ARBs but much lower). Mechanism: block angiotensin II at the AT1 receptor without affecting bradykinin metabolism, so no cough. EQUAL EFFICACY to ACE inhibitors for HFrEF, blood pressure control, and renal protection. Monitoring is identical to ACE inhibitors: K+, creatinine, BP. SAME contraindications: pregnancy, bilateral RAS, history of angioedema (though risk is much lower). Patient teaching: still avoid K+ supplements and salt substitutes; report symptoms suggesting angioedema. ARBs are typically the agent of choice when angioedema or refractory cough has eliminated ACE inhibitors as an option.
Key Points
- •ARBs avoid the bradykinin cough by blocking the receptor downstream.
- •Equal HF efficacy to ACE inhibitors at equivalent doses.
- •Same monitoring and contraindications (cautious in prior angioedema).
5. ARNI and Combination Therapy
Sacubitril/valsartan (Entresto) combines an ARB (valsartan) with a NEPRILYSIN INHIBITOR (sacubitril) that prevents breakdown of natriuretic peptides — improving vasodilation, natriuresis, and HF outcomes. Switch from ACE to ARNI requires a 36-hour washout period to avoid additive angioedema risk. Current guidelines recommend ARNI as the preferred RAAS-targeting agent in HFrEF for many patients. Combining ACE inhibitor + ARB is contraindicated (additive hyperkalemia, renal injury, and angioedema without benefit). The fourth pillar of guideline-directed HF therapy — SGLT2 inhibitors (dapagliflozin, empagliflozin) — provides additional mortality benefit regardless of diabetes status, completing the modern regimen of beta-blocker + ACEi/ARB/ARNI + MRA + SGLT2i.
Key Points
- •Sacubitril/valsartan (Entresto) is ARB + neprilysin inhibitor; preferred over ACE/ARB alone.
- •Switch ACE → ARNI requires 36-hour washout.
- •Never combine ACE + ARB; SGLT2 inhibitors are the modern fourth pillar.
6. Patient Education Pearls
Beta-blockers: take with food to reduce dizziness; do not stop abruptly; carvedilol can cause orthostatic hypotension at initial doses — get up slowly. ACE inhibitors: dry cough is common, not dangerous, may take weeks to resolve after switching; SWELLING OF LIPS OR TONGUE is emergency, call 911 immediately; avoid salt substitutes (contain KCl) and OTC potassium supplements; report dizziness, fatigue, or change in urination. ARBs: same teaching minus the cough. ALL THREE: never take with NSAIDs chronically (NSAIDs raise BP, blunt response, and add renal toxicity); monitor weight daily (weight gain > 2 lb/day or 5 lb/week signals fluid retention requiring follow-up); take medications same time every day to maintain blood levels.
Key Points
- •Beta-blockers: never stop abruptly; take with food.
- •ACE inhibitors: cough is harmless but lip/tongue swelling is emergent.
- •All three: avoid chronic NSAIDs and OTC K+ supplements.
7. Studying Heart Failure Medications with NurseIQ
Photograph a heart failure medication practice question from your course or review book, or upload up to 5 PDF pages, and NurseIQ returns the answer with a short rationale. Detailed mode adds the key concept and a study tip, and Detailed and Expert modes also explain why the other options are wrong. Ask the tutor chat to walk through anything still unclear, or build a study guide on heart failure medications and review it with flashcards. This content is for educational purposes only and does not constitute medical advice.
Key Points
- •Photograph a practice question or upload up to 5 PDF pages
- •Get the answer with a short rationale, plus the key concept and a study tip in Detailed mode
- •Ask the tutor chat follow-up questions
- •Build a study guide and flashcards on heart failure medications
High-Yield Facts
- Beta-blockers recommended for HFrEF: carvedilol, metoprolol SUCCINATE, bisoprolol only.
- ACE inhibitors raise K+ and creatinine; a creatinine rise up to about 30% is often acceptable.
- ACE inhibitor cough = bradykinin; switch to ARB resolves it.
- Angioedema is a class effect of ACE inhibitors; ARB risk is lower but real.
- Sacubitril/valsartan (Entresto) preferred over ACE/ARB alone in modern guidelines.
Practice Questions
1. A patient on lisinopril develops a persistent dry cough. The provider switches to losartan. What teaching does the nurse provide?
2. Why should metoprolol tartrate NOT be ordered for chronic HF?
3. Pre-administration vitals show HR 48 and BP 95/60. The patient is on carvedilol 12.5 mg BID. What does the nurse do?
Study with AI
Snap a photo of a practice question for the answer and the rationale, then ask the tutor chat follow-up questions.
FAQs
Common questions about this topic
Angiotensin II normally vasoconstricts the efferent arteriole of the glomerulus, maintaining filtration pressure. Blocking it removes that vasoconstriction and lowers GFR, raising serum creatinine. A rise of up to about 30% is generally accepted. Larger rises warrant evaluation for bilateral renal artery stenosis or volume depletion. The drug usually need not be stopped at the lower thresholds; the kidneys reach a new steady state.
Both are guideline-recommended HF beta-blockers, but they differ in receptor profile and dose-titration ease. Carvedilol blocks alpha-1 in addition to beta-1 and beta-2 — broader effect on afterload but more dizziness and slower titration. Metoprolol succinate is beta-1 selective — fewer non-cardiac side effects, simpler titration, but less effect on systemic vascular resistance. Both reduced mortality in major heart failure trials; the choice depends on individual tolerance and provider preference.
No. Angioedema is a class effect, and rechallenge with any ACE inhibitor (including lisinopril, captopril, enalapril, ramipril) is contraindicated. ARBs can usually be substituted, with the patient warned that angioedema risk persists at a lower rate. Sacubitril/valsartan (an ARNI) is contraindicated in patients with a history of angioedema from an ACE inhibitor or ARB (Entresto label). Hydralazine plus nitrate is an alternative HF regimen for these patients.
First-dose hypotension is common, especially in patients who are volume-depleted, on diuretics, or have high renin states. The initial vasodilation can be dramatic. Standard precautions: start at a low dose, monitor BP closely after the first dose, follow the prescriber's instructions about diuretics, and counsel the patient to get up slowly.
Yes. Photograph a heart failure medication practice question from your course or review book, and NurseIQ gives the answer with a short rationale. Detailed mode adds the key concept and a study tip, and Detailed and Expert modes also explain why the other options are wrong. You can ask the tutor chat follow-up questions or build a study guide and flashcards on heart failure medications.